Is It Too Late to Buy Vertex Pharmaceuticals Stock?

26.05.24 15:45 Uhr

Werte in diesem Artikel
Aktien

439,00 EUR 5,05 EUR 1,16%

Indizes

PKT PKT

19.752,3 PKT -156,6 PKT -0,79%

17.721,6 PKT -140,6 PKT -0,79%

5.473,2 PKT -13,9 PKT -0,25%

Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs, and it has been working on diversifying its portfolio to include a wider array of products.Today, the stock has a market capitalization of $115 billion -- that's even higher than industry stalwart Bristol Myers Squibb, which is worth approximately $88 billion. Given Vertex's impressive growth over the years and its not-so-modest valuation, is it too late to invest in the stock, and could it finally be approaching a peak? Or is there a path for Vertex's stock to go even higher?Vertex's business has been growing well over the years, but the one knock on the healthcare stock today is that it's just not generating the type of growth it may need to in order to remain a hot buy. While revenue has increased by 59% from $6.2 billion in 2020 to $9.9 billion in 2023, its quarterly year-over-year growth rate tells a different story.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Ausgewählte Hebelprodukte auf Vertex Pharmaceuticals

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vertex Pharmaceuticals

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: MotleyFool

Nachrichten zu Vertex Pharmaceuticals Inc.

Analysen zu Vertex Pharmaceuticals Inc.

DatumRatingAnalyst
01.08.2019Vertex Pharmaceuticals HoldNeedham & Company, LLC
06.02.2019Vertex Pharmaceuticals HoldMaxim Group
26.10.2018Vertex Pharmaceuticals BuyH.C. Wainwright & Co.
01.10.2018Vertex Pharmaceuticals OverweightCantor Fitzgerald
07.08.2018Vertex Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
26.10.2018Vertex Pharmaceuticals BuyH.C. Wainwright & Co.
01.10.2018Vertex Pharmaceuticals OverweightCantor Fitzgerald
07.08.2018Vertex Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
05.03.2018Vertex Pharmaceuticals BuyMaxim Group
01.02.2018Vertex Pharmaceuticals OverweightBarclays Capital
DatumRatingAnalyst
01.08.2019Vertex Pharmaceuticals HoldNeedham & Company, LLC
06.02.2019Vertex Pharmaceuticals HoldMaxim Group
24.10.2016Vertex Pharmaceuticals NeutralH.C. Wainwright & Co.
29.01.2015Vertex Pharmaceuticals HoldMaxim Group
29.01.2015Vertex Pharmaceuticals HoldNeedham & Company, LLC
DatumRatingAnalyst
14.12.2012Vertex Pharmaceuticals sellGoldman Sachs Group Inc.
05.11.2012Vertex Pharmaceuticals sellGoldman Sachs Group Inc.
04.01.2008Vertex Pharmaceuticals DowngradeWachovia Sec
14.12.2006Vertex Pharmaceuticals DowngradeBanc of America Sec.
22.11.2005Update Vertex Pharmaceuticals Inc.: SellBanc of America Sec.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vertex Pharmaceuticals Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"